UA75327C2 - Immunogenic liposomal compositions - Google Patents

Immunogenic liposomal compositions Download PDF

Info

Publication number: UA75327C2
Authority: UA; Ukraine
Prior art keywords: immunogenic; antigenic; liposomal composition; hydrophobic domain; complex
Prior art date: 1998-09-22

Application number

UA2001031606A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-22

Filing date

1999-09-22

Publication date

2006-04-17

1999-09-22 Application filed filed Critical

2006-04-17 Publication of UA75327C2 publication Critical patent/UA75327C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 118
230000002163 immunogen Effects 0.000 title claims abstract description 82
230000000890 antigenic effect Effects 0.000 claims abstract description 94
238000000034 method Methods 0.000 claims abstract description 82
239000000427 antigen Substances 0.000 claims abstract description 73
108091007433 antigens Proteins 0.000 claims abstract description 71
102000036639 antigens Human genes 0.000 claims abstract description 71
230000002209 hydrophobic effect Effects 0.000 claims abstract description 61
239000002502 liposome Substances 0.000 claims abstract description 51
241001465754 Metazoa Species 0.000 claims abstract description 24
108020001507 fusion proteins Proteins 0.000 claims abstract description 19
102000037865 fusion proteins Human genes 0.000 claims abstract description 19
239000002960 lipid emulsion Substances 0.000 claims abstract description 15
230000001939 inductive effect Effects 0.000 claims abstract description 10
230000009851 immunogenic response Effects 0.000 claims abstract description 5
239000013604 expression vector Substances 0.000 claims abstract 2
108090000623 proteins and genes Proteins 0.000 claims description 94
150000002632 lipids Chemical class 0.000 claims description 66
102000004169 proteins and genes Human genes 0.000 claims description 66
108090000765 processed proteins & peptides Proteins 0.000 claims description 27
229960005486 vaccine Drugs 0.000 claims description 26
230000015572 biosynthetic process Effects 0.000 claims description 21
239000000872 buffer Substances 0.000 claims description 21
238000006243 chemical reaction Methods 0.000 claims description 19
230000003612 virological effect Effects 0.000 claims description 19
239000012528 membrane Substances 0.000 claims description 15
239000002671 adjuvant Substances 0.000 claims description 14
239000003960 organic solvent Substances 0.000 claims description 13
125000000539 amino acid group Chemical group 0.000 claims description 12
239000013598 vector Substances 0.000 claims description 10
230000024932 T cell mediated immunity Effects 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 9
230000001580 bacterial effect Effects 0.000 claims description 9
230000036571 hydration Effects 0.000 claims description 9
238000006703 hydration reaction Methods 0.000 claims description 9
230000036760 body temperature Effects 0.000 claims description 8
239000000843 powder Substances 0.000 claims description 8
238000001704 evaporation Methods 0.000 claims description 7
101710177917 Fimbrial protein Proteins 0.000 claims description 6
239000007791 liquid phase Substances 0.000 claims description 6
239000012062 aqueous buffer Substances 0.000 claims description 5
229910052757 nitrogen Inorganic materials 0.000 claims description 5
239000002691 unilamellar liposome Substances 0.000 claims description 5
239000006185 dispersion Substances 0.000 claims description 4
238000003780 insertion Methods 0.000 claims description 4
230000037431 insertion Effects 0.000 claims description 4
230000004044 response Effects 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000002538 fungal effect Effects 0.000 claims 3
244000045947 parasite Species 0.000 claims 3
230000007969 cellular immunity Effects 0.000 claims 1
230000004927 fusion Effects 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 57
210000004027 cell Anatomy 0.000 description 45
108090000695 Cytokines Proteins 0.000 description 37
102000004127 Cytokines Human genes 0.000 description 35
238000004458 analytical method Methods 0.000 description 23
241000700159 Rattus Species 0.000 description 21
210000001744 T-lymphocyte Anatomy 0.000 description 21
241000699670 Mus sp. Species 0.000 description 18
238000002360 preparation method Methods 0.000 description 18
210000000952 spleen Anatomy 0.000 description 18
238000002255 vaccination Methods 0.000 description 18
239000013615 primer Substances 0.000 description 16
238000012360 testing method Methods 0.000 description 16
239000010408 film Substances 0.000 description 15
108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
241000894006 Bacteria Species 0.000 description 14
238000011534 incubation Methods 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
241000700605 Viruses Species 0.000 description 11
230000028993 immune response Effects 0.000 description 11
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
230000003053 immunization Effects 0.000 description 10
238000002649 immunization Methods 0.000 description 10
208000015181 infectious disease Diseases 0.000 description 10
238000005259 measurement Methods 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
244000068988 Glycine max Species 0.000 description 9
235000010469 Glycine max Nutrition 0.000 description 9
230000009089 cytolysis Effects 0.000 description 9
239000012634 fragment Substances 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000000047 product Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
239000000523 sample Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
238000003556 assay Methods 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
238000012163 sequencing technique Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
230000003321 amplification Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
238000003199 nucleic acid amplification method Methods 0.000 description 6
239000002904 solvent Substances 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000001712 DNA sequencing Methods 0.000 description 5
206010070834 Sensitisation Diseases 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000000844 anti-bacterial effect Effects 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 5
229960003132 halothane Drugs 0.000 description 5
238000005342 ion exchange Methods 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
229910052759 nickel Inorganic materials 0.000 description 5
150000007523 nucleic acids Chemical group 0.000 description 5
239000013049 sediment Substances 0.000 description 5
230000008313 sensitization Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000000527 sonication Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
239000004677 Nylon Substances 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
108700005078 Synthetic Genes Proteins 0.000 description 4
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
239000013613 expression plasmid Substances 0.000 description 4
210000000548 hind-foot Anatomy 0.000 description 4
230000028996 humoral immune response Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
239000006166 lysate Substances 0.000 description 4
230000000813 microbial effect Effects 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
229920001778 nylon Polymers 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
239000012071 phase Substances 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010067484 Adverse reaction Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010018691 Granuloma Diseases 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
102100034349 Integrase Human genes 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 3
230000006838 adverse reaction Effects 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
238000013459 approach Methods 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000001569 carbon dioxide Substances 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000002296 dynamic light scattering Methods 0.000 description 3
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
229960005542 ethidium bromide Drugs 0.000 description 3
239000012530 fluid Substances 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
239000000463 material Substances 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
244000052769 pathogen Species 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
244000144977 poultry Species 0.000 description 3
238000003825 pressing Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
230000003393 splenic effect Effects 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
241000713838 Avian myeloblastosis virus Species 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
101100425522 Caenorhabditis elegans mys-1 gene Proteins 0.000 description 2
241000282465 Canis Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101710082714 Exotoxin A Proteins 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
241000702670 Rotavirus Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229960000458 allantoin Drugs 0.000 description 2
208000030961 allergic reaction Diseases 0.000 description 2
238000000137 annealing Methods 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
229910001873 dinitrogen Inorganic materials 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
150000003278 haem Chemical class 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
235000012907 honey Nutrition 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
-1 octyl glycoside Chemical class 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000003161 ribonuclease inhibitor Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
QLHLYJHNOCILIT-UHFFFAOYSA-N 4-o-(2,5-dioxopyrrolidin-1-yl) 1-o-[2-[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoyl]oxyethyl] butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)CCC1=O QLHLYJHNOCILIT-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
244000003416 Asparagus officinalis Species 0.000 description 1
235000005340 Asparagus officinalis Nutrition 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
101150007809 BAM2 gene Proteins 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
108010082845 Bacteriorhodopsins Proteins 0.000 description 1
241000283725 Bos Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108010073254 Colicins Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
206010014596 Encephalitis Japanese B Diseases 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
101710126498 Envelope glycoprotein K Proteins 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000028180 Glycophorins Human genes 0.000 description 1
108091005250 Glycophorins Proteins 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
101150043522 HO gene Proteins 0.000 description 1
240000005926 Hamelia patens Species 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000884385 Homo sapiens Arylamine N-acetyltransferase 1 Proteins 0.000 description 1
101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
101000969327 Homo sapiens Methylthioribose-1-phosphate isomerase Proteins 0.000 description 1
101000588749 Homo sapiens N-acetylglutamate synthase, mitochondrial Proteins 0.000 description 1
101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
201000005807 Japanese encephalitis Diseases 0.000 description 1
241000710842 Japanese encephalitis virus Species 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
102100021415 Methylthioribose-1-phosphate isomerase Human genes 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102100032618 N-acetylglutamate synthase, mitochondrial Human genes 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
101150027985 NAA35 gene Proteins 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
208000010359 Newcastle Disease Diseases 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
208000006257 Rinderpest Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
206010051511 Viral diarrhoea Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
208000003152 Yellow Fever Diseases 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
101150103426 actR gene Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940037003 alum Drugs 0.000 description 1
101150078331 ama-1 gene Proteins 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
XKNKHVGWJDPIRJ-UHFFFAOYSA-N arsanilic acid Chemical class NC1=CC=C([As](O)(O)=O)C=C1 XKNKHVGWJDPIRJ-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
238000010170 biological method Methods 0.000 description 1
208000003836 bluetongue Diseases 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
150000001784 cerebrosides Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000010217 densitometric analysis Methods 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
230000033687 granuloma formation Effects 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
230000003067 hemagglutinative effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000003453 lung abscess Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
208000006971 mastocytoma Diseases 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000005497 microtitration Methods 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
239000006916 nutrient agar Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
SJWPTBFNZAZFSH-UHFFFAOYSA-N pmpp Chemical compound C1CCSC2=NC=NC3=C2N=CN3CCCN2C(=O)N(C)C(=O)C1=C2 SJWPTBFNZAZFSH-UHFFFAOYSA-N 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
229940016590 sarkosyl Drugs 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
238000004793 spatially offset Raman spectroscopy Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000010409 thin film Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013519 translation Methods 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000011121 vaginal smear Methods 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Dispersion Chemistry (AREA)
Biochemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Pulmonology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

UA2001031606A 1998-09-22 1999-09-22 Immunogenic liposomal compositions UA75327C2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10135198P	1998-09-22	1998-09-22
US40072399A	1999-09-21	1999-09-21
PCT/US1999/020880 WO2000016746A2 (en)	1998-09-22	1999-09-22	Immunogenic liposome compositions

Publications (1)

Publication Number	Publication Date
UA75327C2 true UA75327C2 (en)	2006-04-17

Family

ID=26798150

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001031606A UA75327C2 (en)	1998-09-22	1999-09-22	Immunogenic liposomal compositions

Country Status (30)

Country	Link
EP (1)	EP1115382B1 (pl)
JP (1)	JP2002526436A (pl)
KR (1)	KR100592825B1 (pl)
CN (1)	CN1555254A (pl)
AP (1)	AP2010A (pl)
AT (1)	ATE468108T1 (pl)
AU (1)	AU766772B2 (pl)
BG (1)	BG65675B1 (pl)
BR (1)	BR9914004A (pl)
CA (1)	CA2344173C (pl)
CY (1)	CY1110718T1 (pl)
CZ (1)	CZ20011013A3 (pl)
DE (1)	DE69942393D1 (pl)
DK (1)	DK1115382T3 (pl)
EA (1)	EA004797B1 (pl)
EE (1)	EE200100168A (pl)
ES (1)	ES2345695T3 (pl)
GE (1)	GEP20053444B (pl)
HU (1)	HUP0105391A3 (pl)
ID (1)	ID29082A (pl)
IL (2)	IL141675A0 (pl)
MX (1)	MXPA01002973A (pl)
NO (1)	NO330685B1 (pl)
NZ (2)	NZ510442A (pl)
OA (1)	OA11657A (pl)
PL (1)	PL206260B1 (pl)
SK (1)	SK287670B6 (pl)
UA (1)	UA75327C2 (pl)
WO (1)	WO2000016746A2 (pl)
ZA (1)	ZA200101829B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006235507B2 (en)	2005-04-12	2012-08-30	Duke University	Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2010140377A1 (ja)	2009-06-04	2010-12-09	独立行政法人産業技術総合研究所	マイコプラズマ感染症用ワクチン
EP2701734B1 (en) *	2011-04-26	2019-09-25	Molecular Express, Inc.	Liposomal formulations
WO2015048635A1 (en)	2013-09-27	2015-04-02	Duke University	Mper-liposome conjugates and uses thereof
CA3057715A1 (en) *	2017-04-04	2018-10-11	Avidea Technologies, Inc.	Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
KR102901149B1 (ko) *	2022-09-05	2025-12-17	주식회사 차백신연구소	에멀전 제형의 면역증강제 조성물 및 이의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5374548A (en) *	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
SE462375B (sv) *	1985-10-15	1990-06-18	Morgaardshammar Ab Centro	Traadblock
EP0247497B1 (en) *	1986-05-20	1992-03-04	Wako Pure Chemical Industries, Ltd.	Novel functionalized liposomes and a process for production thereof
FR2754543B1 (fr) *	1996-10-11	1998-12-31	Pasteur Institut	Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires

1999
- 1999-09-02 ID IDW20010900A patent/ID29082A/id unknown
- 1999-09-22 DE DE69942393T patent/DE69942393D1/de not_active Expired - Lifetime
- 1999-09-22 AU AU60351/99A patent/AU766772B2/en not_active Ceased
- 1999-09-22 NZ NZ510442A patent/NZ510442A/en not_active IP Right Cessation
- 1999-09-22 IL IL14167599A patent/IL141675A0/xx active IP Right Revival
- 1999-09-22 CA CA2344173A patent/CA2344173C/en not_active Expired - Fee Related
- 1999-09-22 ES ES99969329T patent/ES2345695T3/es not_active Expired - Lifetime
- 1999-09-22 GE GE4350A patent/GEP20053444B/en unknown
- 1999-09-22 MX MXPA01002973A patent/MXPA01002973A/es not_active IP Right Cessation
- 1999-09-22 JP JP2000573707A patent/JP2002526436A/ja active Pending
- 1999-09-22 EP EP99969329A patent/EP1115382B1/en not_active Expired - Lifetime
- 1999-09-22 BR BR9914004-7A patent/BR9914004A/pt not_active IP Right Cessation
- 1999-09-22 DK DK99969329.4T patent/DK1115382T3/da active
- 1999-09-22 NZ NZ528055A patent/NZ528055A/en not_active IP Right Cessation
- 1999-09-22 EA EA200100269A patent/EA004797B1/ru not_active IP Right Cessation
- 1999-09-22 EE EEP200100168A patent/EE200100168A/xx unknown
- 1999-09-22 AT AT99969329T patent/ATE468108T1/de active
- 1999-09-22 UA UA2001031606A patent/UA75327C2/uk unknown
- 1999-09-22 SK SK322-2001A patent/SK287670B6/sk not_active IP Right Cessation
- 1999-09-22 WO PCT/US1999/020880 patent/WO2000016746A2/en not_active Ceased
- 1999-09-22 CN CNA99811216XA patent/CN1555254A/zh active Pending
- 1999-09-22 OA OA1200100075A patent/OA11657A/en unknown
- 1999-09-22 AP APAP/P/2001/002096A patent/AP2010A/en active
- 1999-09-22 CZ CZ20011013A patent/CZ20011013A3/cs unknown
- 1999-09-22 HU HU0105391A patent/HUP0105391A3/hu unknown
- 1999-09-22 PL PL348604A patent/PL206260B1/pl not_active IP Right Cessation
- 1999-09-22 KR KR1020017003621A patent/KR100592825B1/ko not_active Expired - Fee Related
2001
- 2001-02-27 IL IL141675A patent/IL141675A/en not_active IP Right Cessation
- 2001-03-05 ZA ZA200101829A patent/ZA200101829B/en unknown
- 2001-03-20 NO NO20011406A patent/NO330685B1/no not_active IP Right Cessation
- 2001-03-22 BG BG105372A patent/BG65675B1/bg unknown
2010
- 2010-07-30 CY CY20101100715T patent/CY1110718T1/el unknown

Also Published As

Publication number	Publication date
MXPA01002973A (es)	2003-03-27
DE69942393D1 (de)	2010-07-01
NO330685B1 (no)	2011-06-06
SK287670B6 (sk)	2011-05-06
PL206260B1 (pl)	2010-07-30
ID29082A (id)	2001-07-26
CA2344173C (en)	2010-02-23
BG65675B1 (bg)	2009-06-30
NO20011406D0 (no)	2001-03-20
GEP20053444B (en)	2005-02-25
DK1115382T3 (da)	2010-09-06
WO2000016746A8 (en)	2000-08-10
BR9914004A (pt)	2001-07-24
HK1039064A1 (en)	2002-04-12
JP2002526436A (ja)	2002-08-20
AP2001002096A0 (en)	2001-03-31
CZ20011013A3 (cs)	2002-03-13
CA2344173A1 (en)	2000-03-30
IL141675A0 (en)	2002-03-10
EA200100269A1 (ru)	2001-12-24
HUP0105391A2 (hu)	2002-05-29
AU766772B2 (en)	2003-10-23
SK3222001A3 (en)	2001-09-11
WO2000016746A2 (en)	2000-03-30
NZ510442A (en)	2003-10-31
EA004797B1 (ru)	2004-08-26
AU6035199A (en)	2000-04-10
CN1555254A (zh)	2004-12-15
IL141675A (en)	2007-06-17
OA11657A (en)	2004-12-08
WO2000016746A9 (en)	2000-09-21
AP2010A (en)	2009-06-29
WO2000016746A3 (en)	2000-11-23
KR20010075261A (ko)	2001-08-09
PL348604A1 (en)	2002-06-03
KR100592825B1 (ko)	2006-06-23
ES2345695T3 (es)	2010-09-29
NZ528055A (en)	2005-01-28
ZA200101829B (en)	2002-06-05
CY1110718T1 (el)	2015-06-10
BG105372A (en)	2001-10-31
ATE468108T1 (de)	2010-06-15
HUP0105391A3 (en)	2006-02-28
NO20011406L (no)	2001-04-24
EP1115382B1 (en)	2010-05-19
EE200100168A (et)	2002-06-17
EP1115382A2 (en)	2001-07-18

Publication	Publication Date	Title
JP3288692B2 (ja)	2002-06-04	レスピラトリイ・シンシチアル・ウイルス：ワクチンおよび診断法
AU631377B2 (en)	1992-11-26	Affinity associated vaccine
JP4301415B2 (ja)	2009-07-22	ライム病組み合せ組成物とその使用
JP3518866B2 (ja)	2004-04-12	ワクチン抗原を弱めるための胸腺依存作用を提供するリポゾーム
JP2002509421A (ja)	2002-03-26	グラム陽性菌の表面上のハイブリッド表面タンパク質の供給及び発現
MXPA01012787A (es)	2005-08-26	Polinucleotidos microbianos expresados durante la infeccion de un huesped..
JP4530317B2 (ja)	2010-08-25	減毒化トキシンを含むワクチン製剤
CA2344173C (en)	2010-02-23	Immunogenic liposome compositions
JP3396478B2 (ja)	2003-04-14	ワクチン
CN117721150A (zh)	2024-03-19	一种狂犬病mRNA疫苗、其制备及应用
JP2777894B2 (ja)	1998-07-23	コレラワクチン
CA2271699A1 (en)	1998-05-22	Chimeric ltb vaccines
EP0555333A1 (en)	1993-08-18	ARTIFICIAL VIRUS CASES.
KR0173364B1 (ko)	1999-02-01	서로 다른 기원의 펩타이드 항원이 연결된 폴리펩타이드를 함유하는 리포좀
KR0154576B1 (ko)	1998-11-16	펩타이드 항원을 함유하는 리포좀
HK1039064B (en)	2010-08-13	Immunogenic liposome compositions
Green	1995	The development and use of antigen-antibody-LTB (Ag-MAb-LTB) complexes as immunogens
US20050048065A1 (en)	2005-03-03	Methods and compositions containing antigens having a targeting moiety specific for antigen presenting cells for intranasal immunization